Summary
Acne vulgaris is a disease of the pilosebaceous unit of the skin. It may have profound psychological sequelae. The lesions are due to abnormally adherent keratinocytes causing plugging of the follicular duct followed by accumulation of sebum and keratinous debris. This results in the formation of the primary lesion of acne, the comedo. Inflammation of comedones produces papules, pustules and nodules, which often prompt patients to seek treatment. Various effective treatments include topical anti-inflammatory, antibiotic and peeling agents, oral antibiotics, topical and oral retinoids, and hormonal agonists and antagonists. Useful combination regimens are discussed, and treatment approaches suggested. Mild cases of comedonal acne may respond to a topical retinoid or benzoyl peroxide, while inflammatory lesions benefit from topical antibiotics. More severe inflammatory acne is treated with systemic antibiotics. Recalcitrant cases often require oral isotretinoin or hormonal manipulation.
Similar content being viewed by others
References
Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26: 931–5
Emerson GW, Strauss JS. Acne and acne care. Arch Dermatol 1972; 105: 407–11
Webster GF. Inflammatory acne. Int J Dermatol 1990; 29: 313–7
Sheehan-Dare RA, Hughes BR, Cunliffe WJ. Clinical markers of androgenicity in acne vulgaris. Br J Dermatol 1988; 119: 723–30
Levell MJ, Cawood ML, Burke B, et al. Acne is not associated with abnormal plasma androgens. Br J Dermatol 1989; 120: 649–54
Betti R, Bencini PL, Lodi A, et al. Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. Dermatologica 1990; 181: 109–11
Peserico A, Angeloni G, Bertoli P, et al. Prevalence of polycystic ovaries in women with acne. Arch Dermatol Res 1989; 281: 502–3
Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol 1989; 121: 675–80
Marynick SP, Chakmakjian ZH, McCaffree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983; 308: 981–5
Pochi PE, Shalita AR, Strauss JS, et al. Report of the consensus conference on acne classification. J Am Acad Dermatol 1991; 24: 495–500
Zander E, Weisman S. Treatment of acne vulgaris with salicylic acid pads. Clin Ther 1992; 14: 247–53
Mesquita-Guimaraes J, Ramos S, Tavares MR, et al. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol 1989; 14: 357–60
Jaffe GV, Grimshaw JJ, Constad D. Benzoyl peroxide in the treatment of acne vulgaris: a double-blind, multi-centre comparative study of ‘Quinoderm’ cream and ‘Quinoderm’ cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Curr Med Res Opin 1989; 11: 453–62
Nielsen PG. Topical metronidazole gel. Int J Dermatol 1991; 30: 662–6
Slaga TJ, Klein-Szanto AJ, Triplett LL, et al. Skin tumor promoting activity of benzoyl peroxide a widely used free radical generating compound. Science 1981; 213: 1023–5
Hartley JA, Gibson NW, Kilkenny A, et al. Mouse keratinocytes derived from initiated skin or papillomas are resistant to DNA strand breakage by benzoyl peroxide: a possible mechanism for tumor promotion mediated by benzoyl peroxide. Carcinogenesis 1987; 8: 1827–30
Iverson OH. Skin tumorigenesis and carcinogenesis with 712-dimethyl benza (a)anthracene ultraviolet light and benzoyl peroxide. Carcinogenesis 1988; 9: 803–9
Epstein JH. Photocarcinogenesis promotion studies with benzoyl peroxide and croton oil. J Invest Dermatol 1988; 91: 114–6
Cartwright RA, Hughes BR, Cunliffe WJ. Malignant melanoma, benzoyl peroxide and acne: a pilot epidemiological case-control investigation. Br J Dermatol 1988; 118: 239–42
Hogan DJ, To T, Wilson ER, et al. A study of acne treatments as risk factors for skin cancer of the head and neck. Br J Dermatol 1991; 125: 343–8
Mills Jr OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne. Int J Dermatol 1986; 25: 664–7
Leyden JJ, Kligman AM. Contact sensitization to benzoyl peroxide. Contact Dermatitis 1977; 3: 273–5
Poole RL, Griffith JF, MacMillan FS. Experimental contact sensitization with benzoyl peroxide. Arch Dermatol 1970; 102: 635–9
Nacht S, Yeung D, Beasley Jr JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol 1981; 4: 31–7
Yeung D, Nacht S, Bucks D, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II: effect of concentration. J Am Acad Dermatol 1983; 9: 920–4
Lavker RM, Leyden JJ. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992; 14: 773–80
Kligman A. Results of a pilot study evaluating the compatibility of topical tretinoin in combination with glycolic acid. Cosmetic Dermatology 1993; 6: 28–32
Camera G, Pregliasco P. Early malformation in baby born to mother using tretinoin cream [letter]. Lancet 1992; 339: 687
Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341: 1181–2
Shalita AR, Smith EB, Bauer E. Topical erythromycin vs. clindamycin therapy for acne. Arch Dermatol 1980; 120: 351–5
Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne: results of a multiclinic trial. J Am Acad Dermatol 1982; 7: 50–3
Stoughton RB, Cornell RC, Gange Rw, et al. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin-T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26: 424–9
Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116: 387–91
Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol 1990; 70: 534–7
Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5% solution versus topical clindamycin phosphate 1.0%. Cutis 1982; 29: 624–32
Feucht CL, Allen BS, Chalker DK, et al. Topical erythromycin with zinc and acne. J Am Acad Dermatol 1980; 3: 483–91
Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect on Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984; 11: 86–9
Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489–95
Schachner L, Eaglstein W, Kittles C, et al. Topical erythromycin and zinc therapy for acne. J Am Acad Dermatol 1990; 22: 253–60
Eady EA, Jones CE, Tipper JL, et al. Antibiotic resistant pro-pionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306: 555–6
Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–7
Leyden JJ, McGinley K, Mills OH, et al. Topical antibiotics and topical antimicrobial agents in acne therapy. Acta Derm Venereol Suppl 1980; 89: 75–82
Eady EA, Holland KT, Cunliffe WJ. Should topical antibiotics be used for the treatment of acne vulgaris?. Br J Dermatol 1982; 107: 235–46
Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionobacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline anderyth-romycin. Antimicrob Agents Chemother 1982; 21: 770–2
Esterly NB, Koransky JS, Furey NL, et al. Neutrophil chemo-taxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984; 120: 1308–13
Webster GF, Toso SM, Hegemann L. Inhibition of in vitro granuloma formation by tetracyclines and erythromycin: Involvement of protein kinase C. Arch Dermatol. In press
Eady EA, Cove JH, Blake J, et al. Recalcitrant acne vulgaris: clinical biochemical and microbiological investigation of patients not responding to antibiotic treatment. Br J Dermatol 1988; 118: 415–23
Leyden JJ. Antibiotic resistant acne. Cutis 1976; 17: 593–6
Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–5
Driscoll MS, Rothe MJ, Abrahamian L, et al. Long-term oral antibiotics for acne: is laboratory monitoring necessary?. J Am Acad Dermatol 1993; 28: 595–602
Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol 1987; 16: 591–9
Standiford HC. Tetracyclines and chloramphenicol. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases, 2nd ed. New York: John Wiley & Sons, 1984: 209
Smit F. Minocycline versus doxycycline in the treatment of acne vulgaris. Dermatologica 1978; 157: 186–90
Laux B. Treatment of acne vulgaris: a comparison of doxycycline and minocycline. Dermatologist 1989; 40: 577–81
Olafsson JH, Gudgeirsson J, Eggertsdottir GE, et al. Doxycycline versus minocycline in the treatment of acne vulgaris: a double-blind study. J Dermatol Treatment 1989; 1: 15–7
Eady EA, Cove JH, Hollant KT, et al. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990; 122: 233–44
Hubbell CG, Hobbs ER, Rist T, et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982; 118: 989–92
Akamatsu H, Niwa Y, Kurokawa I, et al. Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism. Arch Dermatol Res 1991; 283: 524–8
Freeman K. Therapeutic focus: minocycline in the treatment of acne. Br J Clin Pract 1989; 43: 112–5
Walter JF, Macknet KO. Pigmentation of osteoma cutis caused by tetracycline. Arch Dermatol 1991; 110: 113–4
Moritz DL, Elewski B. Pigmented postacne osteoma cutis in a patient treated with minocycline: report and review of the literature. J Am Acad Dermatol 1991; 24: 851–3
Dwyer CM, Cuddihy AM, Kerr REI, et al. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 1993; 129: 158–62
Purdue B. An incidental autopsy finding of black thyroid associated with minocycline therapy. Med Sci Law 1992; 32: 148–50
Poliak SC, DiGiovanni JJ, Gross EG, et al. Minocycline-associated tooth discoloration in young adults. JAMA 1985; 254: 2930–2
Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27: S2–S7
Jones DH, Greenwood R, Cunliffe WJ. Dose-response relationship of sebum suppression by 13-cis-retinoic acid in severe acne [letter]. Br J Dermatol 1983; 109: 366
Leyden JJ, McGinley KJ. Effect of 13-cis-retinoic acid on sebum production and propionibacteria acnes in severe nodulocystic acne. Arch Dermatol Res 1982; 272: 331–7
Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982; 6: 766–85
Mezick JA, Chhabria MC, Thorne EG, et al. Topical and oral (P.O.) effects of 13-cis-retinoic acid (13-cis-RA) and all-trans-retinoic acid (RA) on horn-filled utriculi (pseudo-comedones) size in the rhino mouse. J Invest Dermatol 1982; 78: 350
Jones DH, Cunliffe WJ, Holmes RL, et al. Effect of 13-cis-retinoic acid on pilosebaceous duct obstruction. Br J Dermatol 1982; 107 Suppl. 22: 35
Perkins W, Rocket KV, Hodgins MB, et al. The effect of treatment with 13-cis-retinoic acid on the metabolic burst of peripheral blood neutrophils from patients with acne. Br J Dermatol 1991; 124: 429–32
Lavker RM, Leyden JJ, Kligman AM. The antiinflammatory activity of isotretinoin is a major factor in the clearing of acne conglobata. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz, 1989: 207–16
Sidell N, Connor MJ, Chang B, et al. Effects of 13-cis-retinoic acid therapy on human antibody responses to defined protein antigens. J Invest Dermatol 1990; 95: 597–602
Rademaker M, Wallace M, Cunliffe W, et al. Isotretinoin treatment alters steroid metabolism in women with acne. Br J Dermatol 1991; 124: 361–4
Meisel W. Management of severe acne with isotretinoin; An open multicenter study. In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Dunitz, 1989: 197–202
Pittsley RA, Yoder FW. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 1983; 308: 1012–4
Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990; 122: 531–7
Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837–41
Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol 1984; 10: 851–4
Dai WS. Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol 1989; 125: 362–5
Drife J. The benefits of combined oral contraceptives. Br J Obstet Gynaecol 1989; 96: 1255–60
Eden JA. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991; 155: 677–80
Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens: a short review. Postgrad Med J 1978; 54 Suppl. 2: 11–24
Jurzyk RS, Spielvogel RL, Rose LI. Antiandrogens in the treatment of acne and hirsutism. Am Fam Physician 1992; 45: 1803–6
Nader S, Rodriguez-Rigan LJ, Smith KD, et al. Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment. J Am Acad Dermatol 1984; 11: 256–9
Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28: 572–9
Wong RC, Kang S, Heezen JL, et al. Oral ibuprofen and tetra-cycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 1076–81
Dreno B, Amblard P, Agache P, et al. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol 1989; 69: 541–3
Mills CM, Peters TJ, Finlay AY. Does smoking influence acne?. Clin Exp Dermatol 1993; 18: 100–1
Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123–8
Lookingbill DP, Abrams BB, Ellis CN, et al. Inocoterone and acne. The effect of a topical antiandrogen: results of a multi-center clinical trial. Arch Dermatol 1992; 128: 1197–200
Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991; 124: 368–71
Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust 1990; 153: 455–8
Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41: 780–98
Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl 1989; 143: 45–8
Cavicchini S, Caputo R. Long-tern treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl 1989; 143: 40–4
Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris: comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl 1989; 143: 35–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sykes, N.L., Webster, G.F. Acne. Drugs 48, 59–70 (1994). https://doi.org/10.2165/00003495-199448010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199448010-00006